trial

L-carnosine for Schizophrenia

NCTId NCT00177177
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 84 (estimated)
Sponsored by University of Pittsburgh Medical Center
Primary completion 2007-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
84 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-03
Primary completion
2007-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
L-carnosine (dietary supplement)

Sponsors

University of Pittsburgh Medical CenterLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
K.N. Roy Chengappa, MDPrincipal Investigator

Sites

4 total
Bridgeville, United StatesDuBois, United StatesMcKeesport, United StatesPittsburgh, United States

Facts & assertions

4 sourced
Enrollment
84
Phase
NA
Primary Completion Date
2007-11
Status
COMPLETED
relationships
The graph out of here
drug
L-carnosine (dietary supplement)
drug
lead_sponsor
University of Pittsburgh Medical Center
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
K.N. Roy Chengappa, MD
person